Multi-projects collaboration with Sygnature Discovery has been initiated.

02 Sep 2021

Epigeneron Inc., and UK based Sygnature Discovery have signed a multi-projects collaboration agreement to develop drug candidates of novel targets. The two companies will create novel small molecule compounds to first-in-class targets that were identified with Epigeneron’s unique technology, ’the locus-specific ChIP’. Epigeneron’s cutting-edge technology together with Sygnature’s track record of effectively delivering clinical candidate molecules from the hits stage is a great example of the future of drug discovery research and evidence of the global paradigm shift from traditional drug discovery to an open, flexible, and ultimately more innovative approach to drug discovery.